For generations, ovarian cancer has claimed lives not because it was untreatable, but because it was invisible until too late. Now, a research team spanning Manchester and Colorado has developed a blood test that reads the molecular whispers cancer cells leave in the bloodstream — lipid and protein fragments that form a signature detectable with over 90 percent accuracy, even in the disease's earliest stages. The work, published in Cancer Research Communications, represents not merely a diagnostic advance but a potential reordering of when and how medicine meets this particular form of sufferi
New Blood Test Detects Ovarian Cancer Early With 90%+ Accuracy
Early detection of ovarian cancer through this test could improve survival rates and patient outcomes for women diagnosed with the disease.
A biological fingerprint for ovarian cancer, hidden in blood
Mark
So this test looks for lipids and proteins in the blood. How confident are we that these fragments are actually unique to ovarian cancer, and not just markers that show up in other cancers too?
Mimi
That's a fair question. The study tested 832 samples and found the algorithm could recognize patterns specific to ovarian cancer with 93 percent accuracy across all stages. But the source material doesn't detail how the test performs against other cancers or false positives in healthy people.
Luke
Right—and that's a critical gap. We know it's 91 percent accurate in early stages, but we don't know the false positive rate. A test that flags cancer in 91 out of 100 early cases sounds great until you learn it also flags 30 healthy people out of 100. The clinical utility depends on that number.
Mark
What about the algorithm itself? How was it trained, and on what population?
Mimi
The source says it was trained on thousands of patient samples and tested on 832 samples from the Manchester and Colorado study. But we don't know the demographics of those samples, whether they represent the full range of women who might use this test, or how the algorithm might perform in populations it wasn't trained on.
Luke
Exactly. And the study is published but we're not seeing the full methodology here. We know the results, but not whether this was a prospective trial or retrospective analysis of stored samples. That changes what the findings actually mean.
Mark
The researchers mention wanting to do prospective trials next. Does that suggest this hasn't been tested that way yet?
Mimi
It appears so. The current study analyzed existing samples. A prospective trial would follow women forward in time, taking the blood test and then tracking outcomes. That's the gold standard for validating a screening tool.
Luke
And that's the honest part of the reporting—they're not claiming this is ready for clinics tomorrow. They're saying it works in the lab and now they need to prove it works in the real world. That's the right posture.
Le Pouls
- Ovarian cancer kills so effectively in part because current screening tools are poorly suited to catching it before symptoms emerge, leaving women diagnosed late and with diminished options.
- AOA Dx's blood test identifies a biological fingerprint — cancer-shed lipid and protein fragments — that an algorithm trained on thousands of samples can now reliably recognize, achieving 93% detection across all stages.
- In early-stage cases, where the difference between survival and death is most sharply drawn, the test still achieved 91% accuracy — a figure that dwarfs what existing clinical markers can offer.
- The research team, led by Dr. Emma Crosbie of the University of Manchester, is now pressing toward prospective trials to move the test from laboratory validation into real-world clinical settings.
- The path ahead requires proving the test performs as well in routine screening as it does on curated samples — a critical threshold before it can become a standard tool for women at elevated risk.
For generations, ovarian cancer has claimed lives not because it was untreatable, but because it was invisible until too late. Now, a research team spanning Manchester and Colorado has developed a blood test that reads the molecular whispers cancer cells leave in the bloodstream — lipid and protein fragments that form a signature detectable with over 90 percent accuracy, even in the disease's earliest stages. The work, published in Cancer Research Communications, represents not merely a diagnostic advance but a potential reordering of when and how medicine meets this particular form of suffering.
A blood test developed by US-based company AOA Dx may fundamentally change how ovarian cancer is caught — and how often women survive it. The test works by detecting molecular debris that cancer cells naturally shed into the bloodstream: fragments of lipids paired with specific proteins that together form a biological signature unique to the disease. An algorithm trained on thousands of patient samples learns to recognize these subtle patterns, flagging cancer even when it remains in its earliest, most treatable form.
The results, drawn from 832 blood samples and published in Cancer Research Communications, were striking. The test detected ovarian cancer across all disease stages 93 percent of the time, and achieved 91 percent accuracy specifically in early-stage cases. That distinction matters enormously: ovarian cancer is notoriously difficult to catch before symptoms appear, and current clinical markers perform poorly in precisely the window when intervention would be most effective.
The disease itself — rooted in the uncontrolled growth of abnormal cells in the ovaries — remains among the deadliest cancers affecting women, in large part because so many diagnoses come too late. Risk factors include age, obesity, family history, and endometriosis, but no reliable early screening tool has existed to act on that risk proactively.
Dr. Emma Crosbie of the University of Manchester, who led the study, has emphasized the need for prospective trials to validate the test in real-world conditions and determine how it might be woven into existing healthcare systems. AOA Dx's leadership echoes that urgency, framing the next phase as a move from laboratory promise to clinical practice — the harder, slower work of turning a breakthrough into a routine option for women who need it most.
A team of researchers has developed a blood test that can identify ovarian cancer in its earliest stages with more than 90 percent accuracy—a significant leap forward from the diagnostic tools currently available to doctors. The test, created by AOA Dx, a US-based company, works by detecting fragments that cancer cells naturally shed into the bloodstream: a combination of lipids and proteins that act as a biological signature unique to ovarian cancer.
The science behind the test is straightforward in concept but sophisticated in execution. Cancer cells release tiny molecular debris into the blood as they grow and divide. These fragments—lipids paired with specific proteins—create a pattern that researchers can now recognize and measure. AOA Dx developed an algorithm trained on thousands of patient samples to identify these subtle patterns, allowing the test to spot cancer even when it is still in its earliest, most treatable stages.
The research, led by scientists at the universities of Manchester and Colorado and published in Cancer Research Communications, tested 832 blood samples using the AOA Dx platform. The results were striking: the test detected ovarian cancer across all disease stages 93 percent of the time. In early-stage cases specifically, it achieved 91 percent accuracy. This matters because ovarian cancer is notoriously difficult to catch early. Current blood markers used in clinical practice work better for patients who already show symptoms, leaving many women undiagnosed until the disease has progressed.
Ovarian cancer itself remains one of the deadliest cancers affecting women. The disease begins when abnormal cells in the ovaries—walnut-sized organs that produce eggs—grow and multiply uncontrollably. While the exact cause remains unknown, certain factors increase risk: age over 60, obesity, a family history of the disease, never having been pregnant, or having endometriosis. Early detection has historically been the challenge; many women receive a diagnosis only after symptoms appear, when treatment becomes more difficult and outcomes less favorable.
Dr. Emma Crosbie, a professor at the University of Manchester who led the study, emphasized the potential impact. She noted that researchers are eager to move forward with additional prospective trials to validate the test further and understand how it could be integrated into existing healthcare systems. Alex Fisher, chief operating officer and co-founder of AOA Dx, told media outlets that the test can detect the disease "at early stages and with greater accuracy than current tools." The next phase involves real-world testing—moving beyond laboratory samples to see how the test performs in actual clinical practice and whether it can become a routine screening option for women at risk.
Citations marquantes
We are eager to continue advancing this important research through additional prospective trials to further validate and expand our understanding of how this could be integrated into existing healthcare systems.— Dr. Emma Crosbie, University of Manchester
The test can detect the disease at early stages and with greater accuracy than current tools.— Alex Fisher, chief operating officer and co-founder of AOA Dx
Envie de l'histoire complète ?
Lire l'original sur Times Now ↗
Health & Medicine